The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth (Vol 26, 23, 2024)

被引:0
作者
Qian, Jing [1 ,9 ]
Ma, Yanxia [1 ,8 ]
Tahaney, William M. [1 ,2 ,7 ]
Moyer, Cassandra L. [1 ]
Lanier, Amanda [1 ]
Hill, Jamal [1 ]
Coleman, Darian [1 ]
Koupaei, Negar [1 ,5 ]
Hilsenbeck, Susan G. [3 ,4 ]
Savage, Michelle I. [1 ]
Page, Brent D. G. [6 ]
Mazumdar, Abhijit [1 ]
Brown, Powel H. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Dan L Duncan Canc Ctr, Houston, TX USA
[4] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX USA
[6] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
[7] Monte Rosa Therapeut, Boston, MA USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX USA
[9] Univ Texas MD Anderson, UTHealth Houston Grad Sch Biomed Sci, Canc Ctr, Houston, TX USA
关键词
Oxidative stress; Phosphatase; Triple-negative breast cancer;
D O I
10.1186/s13058-024-01814-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The most aggressive form of breast cancer is triple-negative breast cancer (TNBC), which lacks expression of the estrogen receptor (ER) and progesterone receptor (PR), and does not have overexpression of the human epidermal growth factor receptor 2 (HER2). Treatment options for women with TNBC tumors are limited, unlike those with ER-positive tumors that can be treated with hormone therapy, or those with HER2-positive tumors that can be treated with anti-HER2 therapy. Therefore, we have sought to identify novel targeted therapies for TNBC. In this study, we investigated the potential of a novel phosphatase, NUDT5, as a potential therapeutic target for TNBC. Methods: The mRNA expression levels of NUDT5 in breast cancers were investigated using TCGA and METABRIC (Curtis) datasets. NUDT5 ablation was achieved through siRNA targeting and NUDT5 inhibition with the small molecule inhibitor TH5427. Xenograft TNBC animal models were employed to assess the effect of NUDT5 inhibition on in vivo tumor growth. Proliferation, death, and DNA replication assays were conducted to investigate the cellular biological effects of NUDT5 loss or inhibition. The accumulation of 8-oxo-guanine (8-oxoG) and the induction of γH2AX after NUDT5 loss was determined by immunofluorescence staining. The impact of NUDT5 loss on replication fork was assessed by measuring DNA fiber length. Results: In this study, we demonstrated the significant role of an overexpressed phosphatase, NUDT5, in regulating oxidative DNA damage in TNBCs. Our findings indicate that loss of NUDT5 results in suppressed growth of TNBC both in vitro and in vivo. This growth inhibition is not attributed to cell death, but rather to the suppression of proliferation. The loss or inhibition of NUDT5 led to an increase in the oxidative DNA lesion 8-oxoG, and triggered the DNA damage response in the nucleus. The interference with DNA replication ultimately inhibited proliferation. Conclusions: NUDT5 plays a crucial role in preventing oxidative DNA damage in TNBC cells. The loss or inhibition of NUDT5 significantly suppresses the growth of TNBCs. These biological and mechanistic studies provide the groundwork for future research and the potential development of NUDT5 inhibitors as a promising therapeutic approach for TNBC patients. © The Author(s) 2024.
引用
收藏
页数:1
相关论文
共 50 条
[21]   EPAC inhibitor suppresses angiogenesis and tumor growth of triple-negative breast cancer [J].
Li, Zishuo ;
Liu, Qiao ;
Cai, Yuhao ;
Ye, Na ;
He, Zinan ;
Yao, Yuying ;
Ding, Yi ;
Wang, Pingyuan ;
Qi, Cuiling ;
Zheng, Lingyun ;
Wang, Lijing ;
Zhou, Jia ;
Zhang, Qian -Qian .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2024, 1870 (04)
[22]   Exosomes as a novel nanomedicine platform for personalized triple-negative breast cancer therapy [J].
Mehata, Abhishesh Kumar ;
Gupta, Niharika ;
Muthu, Madaswamy S. .
NANOMEDICINE, 2023, 18 (06) :501-504
[23]   Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer [J].
Schipilliti, Francesca Matilde ;
Drittone, Denise ;
Mazzuca, Federica ;
La Forgia, Daniele ;
Guven, Deniz Can ;
Rizzo, Alessandro .
HELIYON, 2024, 10 (07)
[24]   Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy [J].
Yu, Bin ;
Luo, Junjie ;
Yang, Yifei ;
Zhen, Ke ;
Shen, Binjie .
JOURNAL OF GENE MEDICINE, 2024, 26 (01)
[25]   Circular RNAs as novel biomarkers in triple-negative breast cancer: a systematic review [J].
Foruzandeh, Zahra ;
Dorabadi, Davood Ghavi ;
Sadeghi, Farzaneh ;
Zeinali-Sehrig, Fatemeh ;
Zaefizadeh, Mohammad ;
Rahmati, Yazdan ;
Alivand, Mohammad Reza .
MOLECULAR BIOLOGY REPORTS, 2022, 49 (10) :9825-9840
[26]   CCL5 as a potential immunotherapeutic target in triple-negative breast cancer [J].
Dandan Lv ;
Yan Zhang ;
Ha-Jeong Kim ;
Lixing Zhang ;
Xiaojing Ma .
Cellular & Molecular Immunology, 2013, 10 :303-310
[27]   CCL5 as a potential immunotherapeutic target in triple-negative breast cancer [J].
Lv, Dandan ;
Zhang, Yan ;
Kim, Ha-Jeong ;
Zhang, Lixing ;
Ma, Xiaojing .
CELLULAR & MOLECULAR IMMUNOLOGY, 2013, 10 (04) :303-310
[28]   Systemic treatment in triple-negative breast cancer patients - standard and novel approaches [J].
Debska-Szmich, Sylwia ;
Potemski, Piotr .
ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (06) :399-414
[29]   Circular RNAs as novel biomarkers in triple-negative breast cancer: a systematic review [J].
Zahra Foruzandeh ;
Davood Ghavi Dorabadi ;
Farzaneh Sadeghi ;
Fatemeh Zeinali-Sehrig ;
Mohammad Zaefizadeh ;
Yazdan Rahmati ;
Mohammad Reza Alivand .
Molecular Biology Reports, 2022, 49 :9825-9840
[30]   Immunological therapy: A novel thriving area for triple-negative breast cancer treatment [J].
Wang, Xiangyu ;
Qi, Yihang ;
Kong, Xiangyi ;
Zhai, Jie ;
Li, Yalun ;
Song, Yan ;
Wang, Jing ;
Feng, Xiaoli ;
Fang, Yi .
CANCER LETTERS, 2019, 442 :409-428